Pharmaceutical compositions comprising glitazones and Nrf2 activators
The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis.
1. A method of treating a patient having multiple sclerosis comprising the co-administration of therapeutically effective amounts of dimethyl fumarate and a PPAR gamma agonist selected from pioglitazone and pioglitazone hydrochloride to said patient.
2. A method of treating a patient having clinically isolated syndrome (CIS) comprising the co-administration of therapeutically effective amounts of dimethyl fumarate and a PPAR gamma agonist selected from pioglitazone and pioglitazone hydrochloride to said patient.
3. The method according to claim 1 , wherein the PPAR gamma agonist is pioglitazone administered at a daily oral dosage of about 15 mg.
4. The method according to claim 1 , wherein dimethyl fumarate is administered at a daily oral dosage of about 120 mg.
5. The method according to claim 1 , wherein the PPAR gamma agonist is pioglitazone hydrochloride.
6. The method according to claim 1 , wherein said dimethyl fumarate is administered at a daily dosage of 1 to 20 mg per kg body weight.
7. The method according to claim 1 , wherein said dimethyl fumarate is administered at a daily dosage of 2 to 15 mg per kg body weight.
8. The method according to claim 1 , wherein said dimethyl fumarate is administered at a daily dosage of 3 to 12 mg per kg body weight.
9. The method according to claim 1 , wherein said dimethyl fumarate is administered at a daily dosage of about 3.4 mg per kg body weight.
10. The method according to claim 1 , wherein said dimethyl fumarate is administered at a daily dosage of about 7 mg per kg body weight.
11. The method according to claim 1 , wherein said dimethyl fumarate is administered at a daily dosage of about 10 mg per kg body weight.
12. The method according to claim 1 , wherein said administration is an oral administration.
13. The method according to claim 1 , wherein said dimethyl fumarate is administered once or twice daily.
14. The method according to claim 1 , wherein the PPAR gamma agonist is pioglitazone administered at a daily oral dosage of about 30 mg.
15. The method according to claim 1 , wherein the PPAR gamma agonist is pioglitazone administered at a daily oral dosage of about 45 mg.
16. The method according to claim 1 , wherein dimethyl fumarate is administered at a daily oral dosage of about 240 mg.
17. The method according to claim 1 , wherein dimethyl fumarate is administered at a daily oral dosage of about 360 mg.
18. The method according to claim 1 , wherein dimethyl fumarate is administered at a daily oral dosage of about 480 mg.
19. The method according to claim 1 , wherein dimethyl fumarate is administered at a daily oral dosage of about 600 mg.
20. The method according to claim 1 , wherein dimethyl fumarate is administered at a daily oral dosage of about 720 mg.
21. The method according to claim 1 , wherein the PPAR gamma agonist is pioglitazone.
22. The method according to claim 2 , wherein the PPAR gamma agonist is pioglitazone administered at a daily oral dosage of about 15 mg.
23. The method according to claim 2 , wherein dimethyl fumarate is administered at a daily oral dosage of about 120 mg.
24. The method according to claim 2 , wherein the PPAR gamma agonist is pioglitazone hydrochloride.
25. The method according to claim 2 , wherein said dimethyl fumarate is administered at a daily dosage of 1 to 20 mg per kg body weight.
26. The method according to claim 2 , wherein said dimethyl fumarate is administered at a daily dosage of 2 to 15 mg per kg body weight.
27. The method according to claim 2 , wherein said dimethyl fumarate is administered at a daily dosage of 3 to 12 mg per kg body weight.
28. The method according to claim 2 , wherein said dimethyl fumarate is administered at a daily dosage of about 3.4 mg per kg body weight.
29. The method according to claim 2 , wherein said dimethyl fumarate is administered at a daily dosage of about 7 mg per kg body weight.
30. The method according to claim 2 , wherein said dimethyl fumarate is administered at a daily dosage of about 10 mg per kg body weight.
31. The method according to claim 2 , wherein said administration is an oral administration.
32. The method according to claim 2 , wherein said dimethyl fumarate is administered once or twice daily.
33. The method according to claim 2 , wherein the PPAR gamma agonist is pioglitazone administered at a daily oral dosage of about 30 mg.
34. The method according to claim 2 , wherein the PPAR gamma agonist is pioglitazone administered at a daily oral dosage of about 45 mg.
35. The method according to claim 2 , wherein dimethyl fumarate is administered at a daily oral dosage of about 240 mg.
36. The method according to claim 2 , wherein dimethyl fumarate is administered at a daily oral dosage of about 360 mg.
37. The method according to claim 2 , wherein dimethyl fumarate is administered at a daily oral dosage of about 480 mg.
38. The method according to claim 2 , wherein dimethyl fumarate is administered at a daily oral dosage of about 600 mg.
39. The method according to claim 2 , wherein dimethyl fumarate is administered at a daily oral dosage of about 720 mg.
40. The method according to claim 2 , wherein the PPAR gamma agonist is pioglitazone.